98
Participants
Start Date
February 5, 2024
Primary Completion Date
March 1, 2026
Study Completion Date
March 1, 2026
HMBD-001
HMBD-001 is a humanized Immunoglobulin G1 (IgG1) anti-Human Epidermal Growth Factor Receptor 3(HER3) monoclonal antibody (mAb). It is administered intravenously (IV) weekly
Docetaxel
Docetaxel 75 mg/m\^2 or 60 mg/m IV once every 3 weeks
Cetuximab
Cetuximab 400 mg/m\^2 IV loading dose, followed by 250 mg/m\^2 weekly
RECRUITING
GenesisCare North Shore, Sydney
RECRUITING
Westmead Hospital, Westmead
WITHDRAWN
Cabrini Health, Malvern
WITHDRAWN
ICON Cancer Centre South Brisbane, Brisbane
RECRUITING
Greenslopes Private Hospital, Greenslopes
RECRUITING
Southern Oncology Clinical Research Unit, Adelaide
RECRUITING
Linear Clinical Research, Perth
RECRUITING
Peninsula & South Eastern Haematology and Oncology Group, Frankston
RECRUITING
The Institute of Oncology, ARENSIA Exploratory Medicine Phase I Unit, Chisinau
RECRUITING
National Cancer Centre Singapore, Singapore
RECRUITING
Tan Tock Seng Hospital, Singapore
RECRUITING
Chungbuk National University Hospital, Cheongju-si
RECRUITING
CHA Bundang Medical Center, CHA University, Seongnam-si
RECRUITING
Korea University Anam Hospital, Seoul
RECRUITING
Severance Hospital, Seoul
NOT_YET_RECRUITING
The Catholic University of Korea St. Vincent's Hospital, Suwon
RECRUITING
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
RECRUITING
National Cheng Kung University Hospital, Tainan City
RECRUITING
Taipei Medical University - Shuang Ho Hospital, Taipei
RECRUITING
Taipei Veterans General Hospital, Taipei
Lead Sponsor
Merck KGaA, Darmstadt, Germany
INDUSTRY
Hummingbird Bioscience
INDUSTRY